These findings collectively imply that inhibition of Helz2 function clearly upregulates the Leprb expression in the liver and that hepatic Helz2 is a potential target molecule for the treatment of fatty liver and hyperglycemia. Here, HELZ2 is linked to Hepatic steatosis.